CohBar, Inc. (CWBR)
- Previous Close
0.9003 - Open
0.9507 - Bid --
- Ask --
- Day's Range
0.9003 - 0.9003 - 52 Week Range
0.5800 - 6.9000 - Volume
21 - Avg. Volume
2,240 - Market Cap (intraday)
2.617M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-4.3700 - Earnings Date Apr 23, 2024 - Apr 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
www.cohbar.comRecent News: CWBR
Performance Overview: CWBR
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CWBR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CWBR
Valuation Measures
Market Cap
2.62M
Enterprise Value
-9.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.28
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.31%
Return on Equity (ttm)
-83.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.69M
Diluted EPS (ttm)
-4.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
12.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.5M